Holen Sie sich die Stockscreener-App
14.81
2.31%
-0.35
Handel nachbörslich:
14.81
Schlusskurs vom Vortag:
$15.16
Offen:
$15.12
24-Stunden-Volumen:
1.03M
Relative Volume:
0.49
Marktkapitalisierung:
$1.76B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-3.7781
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
+2.14%
1M Leistung:
+20.31%
6M Leistung:
+38.93%
1J Leistung:
+33.91%
1-Tages-Spanne:
$14.63
$15.40
1-Wochen-Bereich:
$13.80
$16.09
52-Wochen-Spanne:
$6.99
$16.20
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
14.81 | 1.76B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
Arcutis Biotherapeutics: Topical Derm Player Continues To Execute (NASDAQ:ARQT) - Seeking Alpha
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.1% Following Analyst Upgrade - Defense World
Jefferies lifts Arcutis stock price target to $19, retains Buy rating - Investing.com Canada
Jefferies lifts Arcutis stock price target to $19, retains Buy rating By Investing.com - Investing.com South Africa
Hand Eczema Clinical and Non-Clinical Studies, Key Companies, - openPR
Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Target Price at $18.00 - Defense World
Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up - Simply Wall St
Arcutis Biotherapeutics announces new data from two posters at 2025 AAD - TipRanks
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Unveils Promising Data on ZORYVE® Cream and Foam at AAD 2025 - GuruFocus.com
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic ... - The Bakersfield Californian
Breakthrough Phase 3 Results: New Treatment Shows 97% Success Rate in Major Skin Conditions - StockTitan
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average - Yahoo Finance
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherape - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Seborrhoeic Dermatitis Clinical and Non-Clinical Studies, Key - openPR
Arcutis Issues 27,000 RSUs: What This Employee Compensation Move Signals - StockTitan
Arcutis Biotherapeutics (ARQT) – Research Analysts’ Recent Ratings Updates - Defense World
Arcutis Biotherapeutics Inc Stock: Executives Sell Shares Following Strong Results - sharewise
Arcutis Biotherapeutics director sells $130,048 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics executive sells $49,407 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics CEO Todd Watanabe sells $327,019 in stock - Investing.com India
Arcutis Biotherapeutics executive sells $49,407 in stock - Investing.com
Arcutis Biotherapeutics’ general counsel Matsuda sells $42,520 in stock By Investing.com - Investing.com UK
Seborrhea Clinical and Non-Clinical Studies, Key Companies, - openPR
Arcutis Biotherapeutics Shines in Earnings Call - TipRanks
Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $15.00 - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Given New $21.00 Price Target at Mizuho - MarketBeat
Decoding Arcutis Biotherapeutics Inc (ARQT): A Strategic SWOT In - GuruFocus.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Posts Earnings Results, Beats Expectations By $0.19 EPS - MarketBeat
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - The Manila Times
Can Arcutis' New ZORYVE Clinical Data Transform Treatment Options for Dermatology Patients? - StockTitan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Mizuho Boosts Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target to $21.00 - Defense World
Arcutis Biotherapeutics' (ARQT) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial - ACCESS Newswire
FDA accepts sNDA for Arcutis’ Zoryve in young children with eczema - The Pharma Letter
Arcutis: ZORYVE Net Product Revenue Growth Isn't Only Opportunity On Deck (ARQT) - Seeking Alpha
Strong Sales Growth and Financial Stability Drive Buy Rating for Arcutis Biotherapeutics - TipRanks
Mizuho lifts Arcutis stock price target to $21 from $20 By Investing.com - Investing.com Australia
FDA Accepts sNDA for Zoryve Cream for Atopic Dermatitis Treatment in Young Children - Managed Healthcare Executive
Arcutis rises as lead product undergoes FDA review for label expansion - MSN
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations - Seeking Alpha
Strong Buy Rating for Arcutis Biotherapeutics Driven by Zoryve’s Growth and Market Expansion - TipRanks
Arcutis Biotherapeutics rises on strong sales of skin disease drug - TradingView
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arcutis Biotherapeutics Inc-Aktie (ARQT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burnett Patrick | See Remarks |
Mar 04 '25 |
Sale |
13.28 |
954 |
12,673 |
166,089 |
| Watanabe Todd Franklin | See Remarks |
Mar 03 '25 |
Sale |
13.03 |
20,880 |
272,089 |
934,249 |
| Watanabe Todd Franklin | See Remarks |
Mar 04 '25 |
Sale |
13.28 |
4,135 |
54,930 |
930,114 |
| Welgus Howard G. | Director |
Mar 03 '25 |
Sale |
13.00 |
10,000 |
130,048 |
131,944 |
| Matsuda Masaru | See Remarks |
Mar 03 '25 |
Sale |
13.03 |
3,263 |
42,520 |
209,429 |
0.49%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):